

Informed Consent: Advising Patients and Parents About Complementary and Alternative Medicine Therapies

AUTHORS: Joan Gilmour, LLB, JSD,^a Christine Harrison, MA, PHD,^b Leyla Asadi, MD,^c Michael H. Cohen, JDA, MBA,^d and Sunita Vohra, MD, MSc^{e,f}

^aOsgoode Hall Law School, York University, Toronto, Ontario, Canada; ^bDepartment of Bioethics, SickKids Hospital, Toronto, Ontario, Canada; ^cDepartments of ^eMedicine and ^fPediatrics, Faculty of Medicine, University of Alberta, Edmonton, Alberta, Canada; ^dFenton Nelson LLP, Los Angeles, California; and ^eCARE Program for Integrative Health & Healing, Stollery Children's Hospital, Edmonton, Alberta, Canada

KEY WORDS

complementary therapies, evidence-based practice, acupuncture, nausea, neoplasms

ABBREVIATIONS

CINV—chemotherapy-induced nausea and vomiting

NIH—National Institutes of Health

CAM—complementary and alternative medicine

www.pediatrics.org/cgi/doi/10.1542/peds.2010-2720H

doi:10.1542/peds.2010-2720H

Accepted for publication Mar 30, 2011

Address correspondence to Sunita Vohra, MD, MSc, Edmonton General Hospital, 8B19-11111 Jasper Ave, Edmonton, Alberta, Canada T5K 0L4. E-mail: svohra@ualberta.ca

PEDIATRICS (ISSN Numbers: Print, 0031-4005; Online, 1098-4275).

Copyright © 2011 by the American Academy of Pediatrics

FINANCIAL DISCLOSURE: *The authors have indicated they have no financial relationships relevant to this article to disclose.*

abstract

Although research on complementary and alternative medicine (CAM) therapies is still limited, systematic reviews have revealed sufficient evidence to conclude that CAM can be effective for certain conditions. In this article we discuss clinicians' responsibilities to inform parents/patients about CAM alternatives and use the example of acupuncture for chemotherapy-induced nausea and vomiting. Chemotherapy-induced nausea and vomiting remain significant adverse effects of cancer therapy, and some patients cannot find relief with standard therapies. When making decisions for a child with a life-threatening illness, parents must consider all reasonable options and decide what is in the child's best interests. A physician's failure to provide parents with relevant information regarding therapies with the prospect of therapeutic benefit impedes their ability to make an informed decision. Physicians have the ethical duty of beneficence; they must be aware of current research in pain and symptom management and other aspects of care. A physician's duty of care does not necessarily include the obligation to provide information about therapies outside the range of conventional treatment or those not yet supported in the medical literature. However, as CAM therapies such as acupuncture become better studied and their safety and efficacy are established, the scope of disclosure required may expand to include them. The legal and ethical obligation to obtain informed consent to treatment requires disclosure and discussion of therapies when there is reliable evidence of potential therapeutic benefit. At the same time, the more limited state of knowledge regarding effects of a particular therapy in the pediatric population must be factored into decision-making when treating a child. *Pediatrics* 2011;128:S187–S192

The parents of 6-year-old Jake, a young boy with medulloblastoma, are distressed by the nausea and vomiting he is suffering as a result of chemotherapy. His chemotherapy-induced nausea and vomiting (CINV) occur spontaneously and are also being triggered by sights, sounds, and smells for up to 2 weeks after a course of chemotherapy. His parents believe that this is preventing him from eating properly and that the psychological toll of the adverse effects of treatment are limiting his ability to combat the cancer. They ask Jake's oncologist about other options to alleviate his nausea. He has tried dimenhydrinate and dexamethasone in addition to ondansetron, but like metoclopramide, they have not provided Jake with sufficient relief. Jake's oncologist recommended that he continue with nabilone, a synthetic cannabinoid; however, Jake refuses to continue this drug, because it makes him feel dizzy and anxious. Disappointed, his parents resign themselves to the possibility that Jake might not find relief from his CINV.

While communicating online with other families of patients with cancer, Jake's parents discover that a consensus panel through the US National Institutes of Health (NIH) has recognized the effectiveness of acupuncture for alleviating CINV.^{1,2} They ask their oncologist about it, but his response is non-committal. Jake's parents take him out on intermittent passes from the hospital to an acupuncturist in the community. They are delighted to see that his nausea and vomiting are much improved after each acupuncture session. Jake begins to regain his appetite, gains weight, and generally has a better sense of well-being.

Jake's parents are upset that their physician, whom they believe also had access to information outlining the potential benefits of acupuncture, did not tell them that it was potentially a safe

and effective treatment option for CINV. When they describe their son's improvements after acupuncture, their physician dismisses them as a "placebo effect." Jake's parents are concerned that the physician instead offered antiemetic medications that, from their point of view, only created more problems and unnecessary adverse effects.

Although research continues to develop, there is now evidence that some complementary and alternative medicine (CAM) therapies can be effective in treating certain conditions.^{1,3,4} CAM use is especially prevalent among people with certain types of illness: "chronic, recurrent and incurable conditions such as asthma, allergies, cancer, cystic fibrosis, HIV infection, inflammatory bowel disease and specific health needs."⁵ Children with these conditions commonly use CAM therapies concurrently with conventional medical care.^{6,7}

In our scenario, the parents learned through online social networks, not their son's physician, that a CAM therapy (acupuncture) might ease their son's suffering. What responsibilities does a clinician have to bring CAM alternatives to the attention of patients/parents? In this article we (1) explain clinicians' obligations when obtaining informed consent to treatment and (2) discuss clinicians' responsibility to tell parents/patients about a potentially beneficial CAM therapy.

ETHICS

One way of thinking about the ethical issues in this case is in terms of the nature of the relationships that exist between Jake as a child and patient and those who are caring for him and what responsibilities are owed by the physicians and parents to him as a child patient.⁸

Informed Choice

Because he is a young child, Jake has minimal control over the decisions that are made about his treatment. The primary responsibility for such decisions rests with his parents. As those closest to him, they have the best knowledge of him as a person and, therefore, how he will be affected by his illness and treatment; they also have the greatest interest in his well-being and achieving a good outcome.^{9,10} Making decisions for a child with a life-threatening illness involves a huge burden of responsibility for parents. They must attempt to consider all reasonable options that are available and decide according to what they believe will be best for their child. To do this they must have all relevant information. The physician, as gatekeeper of this information, must ensure that the parents have the information they need and are able to understand it. Providing this information is part of the informed-consent obligation, which applies to pediatric as well as adult care.

When parents are informed about the whole plan of care, they should receive not just information about the primary treatment (in Jake's case, chemotherapy) but also about other conventional alternatives, including nontreatment, and what is likely to happen with each of them (ie, benefits and risks such as adverse effects and how they will be managed). Parents also need to know about reasonable CAM options. Physicians who are not convinced that CAM treatments are beneficial may be reluctant to discuss them with patients or their substitute decision-makers, which is reasonable when research data are unavailable or inconclusive. When there is reliable evidence from research indicating that symptoms may be relieved by a particular intervention, even if that intervention might be considered outside conventional

health care, physicians should inform patients and/or substitute decision-makers about it, especially when conventional therapies have been unsuccessful. When physicians are not capable of providing the treatment themselves, they can offer to arrange a referral.¹¹ In any event, the physician should disclose and discuss the relevant therapy. Otherwise, he is impeding Jake's parents from fulfilling their responsibility to make the best possible decisions for their son and doing whatever they can to relieve his suffering.

The Goals of Medicine

To better understand the responsibilities that physicians have to their patients, it is important to be mindful of the principal goals of medicine in relation to patients: to promote patients' good, as defined by the patients themselves or, in the case of young children, by their parents working collaboratively with physicians and other health care providers; to preserve life (in keeping with the principles of sanctity of life and beneficence); and to alleviate suffering (in keeping with the principle of nonmaleficence, which requires us to prevent or refrain from causing harm).^{12,13}

The treatments necessary for patients with life-threatening illnesses will often cause them suffering, so the diligent physician will pay special attention to pain and symptom management. He or she should be aware of current research in the area, be available to assist families with their research and decision-making, and be as creative and aggressive as possible (consistent with safety and efficacy) in the alleviation of suffering, especially for young children, who are less able to describe their symptoms and communicate their distress.^{14,15}

LAW

Informed Consent

In the United States and Canada, clinicians have a legal duty to obtain informed consent for treatment from patients or, if they are incapable of deciding for themselves, from substitute decision-makers, usually their parents. Patients/parents must be given material information about the treatment proposed, its risks and benefits, and alternative courses of action (including nontreatment), that is, the information that a reasonable person in similar circumstances would want to help them decide.^{16–18} Clinicians must also answer specific questions or requests for additional information. Special needs or particular concerns, such as managing adverse effects of treatment, can necessitate even broader disclosure.¹⁹

The duty to obtain informed consent for treatment is based on and reinforces patients' rights to autonomy and bodily integrity. It is recognized in common law and, in some jurisdictions, has been codified in legislation.^{18,20–24} The standard for disclosure is high and has become increasingly demanding over time.²⁵ In Canada and some American states, the test is patient-centered (what the reasonable patient/parents would want to know to decide whether to consent). Some US states²⁶ and some other countries use a profession-centered standard of disclosure (what reasonable health professionals would consider appropriate to disclose).

The obligation to discuss alternative treatment choices in addition to those proposed by the treating physician is not unlimited. Although the boundaries of the obligation have not been well developed in case law, the alternative should offer at least the prospect of some therapeutic benefit; that is, it must be reasonable to consider it to be

an alternative.^{27–29} US Federation of State Medical Boards guidelines for using CAM require “a favorable risk/benefit ratio compared with other treatments for the same condition. . . based on a reasonable expectation that it will result in a favorable patient outcome. . . .”³⁰ The extent of disclosure is driven by the reason it is required: to equip patients/parents with the information needed to make an informed choice. However, even in the realm of conventional care, physicians may disagree about what treatments are appropriate. In that context, it has been suggested that when there is a genuine difference of opinion within the medical community and the treating physician does not support the alternative, there is still a duty to tell the patient about it and why the doctor considers it inappropriate.^{25,28} Some cases have shown a narrower view, holding that the treating physician is only obligated to disclose options that in his or her reasonable medical judgment are appropriate for the patient.^{31,32} This distinction may make little difference in practice because, as 1 court noted, when there is more than 1 medically reasonable treatment and the risk/benefit analysis engaged by the alternatives involves different considerations, then “a reasonable person would want to know about the alternatives and would want the assistance of the doctor's risk/benefit analysis of the various possible treatments. . . .”³³ The physician's assessment and recommendations can help place the treatment options in perspective and assist the patient/parents in making an informed decision.^{34,35}

Discussing CAM Therapies

There is little American or Canadian law on whether the duty to inform patients/parents about alternatives extends to CAM.²⁰ Existing case law focuses on the scope of the duty to

review conventional treatment options, not CAM. However, indications are that any requirement to alert a patient to alternative therapies not accepted by conventional biomedicine would be sharply limited.^{5,20,28,29,36–38,*}

Neither Canadian nor US legal scholars have reported locating a case in which conventional health care providers were found liable for not advising a patient of an unconventional or alternative form of treatment.^{5,36,39} However, disclosure obligations evolve over time. As the evidence for a particular therapy (whether conventional or CAM) grows and it becomes more accepted in the medical literature, clinicians' duty to disclose information about them can be expected to expand accordingly as well. When advising patients about alternative treatments, clinicians should comply with applicable professional and institutional policies.⁴⁰

CLINICAL RESPONSE

Childhood cancer survival rates have climbed steadily over the past decade.⁴¹ Nonetheless, CINV still remain significant and debilitating adverse effects. The current standard of prevention and treatment of CINV—the use of serotonin³ antagonists with or without corticosteroids and adjunctive antiemetic medications—has provided many patients with a substantial degree of control over their symptoms.⁴¹ However, there still remains a minority of patients who do not find relief from standard therapies and for whom other methods of treatments

*See *Moore v Baker* ([1991], US Dist LEXIS 14712 [SD Ga, 1991]) (a physician is not obliged to disclose the possibility of chelation therapy as an alternative to carotid endarterectomy to treat coronary blockage because it is not generally recognized and accepted in the medical community), and *Plumber v State Department of Health* ([1994], 634 So 2d 1347, 1352 [La Ct App]) (disclosure of alternatives to chemotherapy for cancer treatment were not required under the circumstances; the alternative recognized by conventional medicine is to not undergo chemotherapy).

should be considered. In addition, many patients object to taking what they consider excessive or debilitating medication.

More than a decade ago, an NIH consensus conference on acupuncture concluded that there was clear evidence supporting the efficacy of needle acupuncture in treating adult CINV.¹ Although the mechanisms of action are not yet fully understood, the NIH considered there to be considerable evidence that stimulation of acupuncture points is associated with the release of opioid peptides, changes in immune function, and systemic effects from the activation of the pituitary and hypothalamus.¹ A meta-analysis published in 2006 of 11 randomized controlled trials for acupuncture-point stimulation to reduce CINV has corroborated the NIH findings.⁴² The authors concluded that acupuncture-point stimulation is safe and that all methods except noninvasive electrostimulation are effective adjunct therapies for reducing acute vomiting and possibly effective for reducing the severity of acute nausea.⁴² In addition, of 4 recent randomized controlled trials not included in this meta-analysis, the results of 3 of them favored acupuncture-point stimulation,^{43,44} and 1 of them found it ineffective.⁴⁵

The adverse events reported in randomized controlled trials of acupuncture have been mild and short-lived,⁴² and the occurrence of adverse events from properly performed acupuncture is considered rare^{46–49}; the risk of a “serious side effects from acupuncture therapy when performed by a licensed acupuncturist are 1:10 000 to 1:100 000—about the same risk as a serious adverse event from taking penicillin.”⁵⁰ Weiger et al⁵¹ have suggested that patients who seek acupuncture for CINV be advised that the option is acceptable and that doctors consider recommending acupuncture

as an option from the outset. It is significant, however, that although acupuncture on children has been shown to be feasible and acceptable,^{50,52–54} and children have shown little discomfort or fear, only 5 recent studies on the effectiveness of acupuncture-point stimulation for CINV have included pediatric subjects.^{45,55–57}

Cohen⁵⁸ has suggested that, to provide the best possible care, the physician balance 7 important factors when deciding whether to recommend a CAM treatment: (1) severity and acuteness of the illness; (2) curability with conventional treatment; (3) invasiveness, toxicities, and adverse effects of conventional treatment; (4) quality and evidence of safety and efficacy of the CAM treatment; (5) degree of understanding of the risks and benefits of conventional and CAM treatments; (6) knowledge and voluntary acceptance of those risks by the patient; and (7) persistence of the patient's intention to use CAM.

Applying the decision-making framework described in the introduction to this supplemental issue of *Pediatrics*,⁵⁹ there is evidence that acupuncture for CINV is both safe and effective, at least for adults. Conventional treatment with antiemetic medications has failed for Jake. In these circumstances, the physician could discuss the options and recommend acupuncture or, mindful of the lack of research specific to children, inform the parents about this alternative and the state of knowledge regarding children and consider a trial of this CAM therapy as an option. In any event, monitoring of the patient's CINV should continue.

RECOMMENDATIONS

Advising About CAM Therapies: Disclosure Standards

Medical knowledge is continually evolving, as is the scope of physicians' duty of disclosure. As the results of re-

search concerning different forms of CAM become more widely known and are reported in the medical literature, physicians' duty of disclosure could well expand to include informing patients and parents about potentially beneficial CAM options, especially if they involve less risk or fewer adverse effects than conventional therapy. Whether a CAM therapy has attained sufficient medical acceptance for a given condition to trigger an obligation to disclose as part of the informed-consent process would depend on prevailing medical evidence about safety and efficacy. In the example of acupuncture to treat chemotherapy-related nausea, current evidence (including support by the NIH consensus

panel) is likely sufficient to make its disclosure material to patients'/parents' decision about treating the nausea. Consequently, parents should be informed of this option.

Pain and Symptom Management

Physicians should be aware of relevant current research in this area, whether it involves a conventional or CAM therapy, be available to assist families with their research and decision-making regarding all potentially beneficial therapies, and be as creative and aggressive as possible (consistent with safety and efficacy) in the alleviation of suffering, especially for young children, who are less able to describe their symptoms and communicate their distress.^{10,12}

ACKNOWLEDGMENTS

Funding for this project was partially provided by the SickKids Foundation (Toronto, Ontario, Canada). Dr Vohra received salary support from the Alberta Heritage Foundation for Medical Research and the Canadian Institutes of Health Research.

We gratefully acknowledge the contributions of Connie Winther and Soleil Surette for help in literature searching and manuscript preparation, Maya Goldenberg and Andrew Milroy for bioethics research assistance, and Osgoode Hall Law School students (now graduates) Nicola Simmons, David Vitale, Kristine Bitterman, and Janet Chong for assistance with legal research.

REFERENCES

- National Institutes of Health. NIH consensus conference: acupuncture. *JAMA*. 1998; 280(17):1518–1524
- Smallwood C. *The Role of Complementary and Alternative Medicine in the NHS: An Investigation Into the Potential Contribution of Mainstream Complementary Therapies to Healthcare in the UK*. London, United Kingdom: FreshMinds; 2005
- Linde K, Berner MM, Kriston L. St John's wort for major depression. *Cochrane Database Syst Rev*. 2008;(4):CD000448
- Al Fahed KM, Bassler D. Probiotics for prevention of necrotizing enterocolitis in preterm infants. *Cochrane Database Syst Rev*. 2008;(1):CD005496
- Kemper K, Cohen M. Complementary therapies in pediatrics: legal perspectives. In: Perkin R, Swift J, Newton D, Annas N, eds. *Pediatric Hospital Medicine*. 2nd ed. Philadelphia, PA: Wolters Kluwer/Lippincott, Williams & Williams; 2008:70–74
- Barnes PM, Bloom B, Nahin RL. Complementary and alternative medicine use among adults and children: United States, 2007. *Natl Health Stat Report*. 2008;(12):1–23. Available at: www.cdc.gov/nchs/data/nhsr/nhsr012.pdf. Accessed August 10, 2010
- Martel D, Bussieres JF, Theoret Y, et al. Use of alternative and complementary therapies in children with cancer. *Pediatr Blood Cancer*. 2005;44(7):660–668
- Harrison C. Ethics in paediatric practice: primum non nocere is only the beginning. *Paediatr Child Health*. 2007;12(5):379–380
- American Academy of Pediatrics, Committee on Bioethics. Informed consent, parental permission, and assent in pediatric practice. *Pediatrics*. 1995;95(2):314–317
- Canadian Paediatric Society. Treatment decisions regarding infants, children and adolescents. *Paediatr Child Health*. 2004;9(2): 99–114
- Gilmour J, Harrison C, Asadi L, Cohen MH, Vohra S. Referrals and shared or collaborative care: managing relationships with complementary and alternative medicine practitioners. *Pediatrics*. 2011;128(5 pt 4): S181–S186
- Pellegrino ED, Thomasma DC. *For the Patient's Good: The Restoration of Beneficence in Health Care*. New York, NY: Oxford University Press; 1988
- Cassel EJ. The nature of suffering and the goals of medicine. *N Engl J Med*. 1982; 306(11):639–645
- Attig T. Beyond pain: the existential suffering of children. *J Palliat Care*. 1996;12(3): 20–23
- Walco GA, Cassidy RC, Schechter NL. Pain, hurt, and harm: the ethics of pain control in infants and children. *N Engl J Med*. 1994; 331(8):541–544
- Reibl v Hughes* (1980), 2 SCR 880
- Canterbury v Spence* (1972), 464 F 2d 772
- Furrow B, Greaney T, Johnson S, Jost T, Schwartz R. Defining death. In: *Health Law*. 6th ed. St Paul, MN: Thomson West; 2008: 241–244
- Patterson v Hryciuk* (2004), AJ No. 1509, add'l Reasons (2005) Carswell Alta 309(Alta QB)
- Cohen M. The role of informed consent in the delivery of complementary and alternative medical therapies. In: Faass N, ed. *Integrating Complementary Medicine Into Health Systems*. Gaithersburg, MD: Aspen; 2001; 238
- Health Care Consent Act, S.O. 1996, being Sch. A to the Advocacy, Consent and Substitute Decisions Statute Law Amendment Act, S.O. 1996, c. 2
- Health Care (Consent) and Care Facility (Admission) Act, RSBC 1996 (Supp), c. 181
- Consent to Treatment and Health Care Directives Act, RSPEI 1988, c.C-17-2
- Care Consent Act, S.Y. 2003, being Sch. B to the Decision Making, Support and Protection of Adults Act, S.Y. 2003, c. 21
- Picard E, Robertson G. *Legal Liability of Doctors and Hospitals in Canada*. 4th ed. Toronto, Ontario, Canada: Carswell; 2007:151
- King J, Moulton B. Rethinking informed consent: the case for shared medical decision-making. *Am J Law Med*. 2006;32(4): 429–501
- Cohen M, Kemper K. Complementary therapies in pediatrics: a legal perspective. *Pediatrics*. 2005;115(3):774–780
- Seney v Crooks* (1998), AJ No. 1060 (QL); 1998 ABCA 316 (CA)

29. *Podzik (Next Friend of) v Wilson* (2002), AJ No. 450 (QB)
30. Federation of State Medical Boards, Special Committee for the Study of Unconventional Health Care Practices. *Model Guidelines for the Use of Complementary and Alternative Therapies in Medical Practice*. Dallas, TX: Federation of State Medical Boards; 2002. Available at: www.fsmb.org/pdf/2002_grpol_Complementary_Alternative_Therapies.pdf. Accessed March 14, 2011
31. *Bucknam v Kostuik* (1983), 44 OR (2d) 102, aff'd (1986), 55 OR (2d) 187 (CA)
32. *Ferron v Yadav* (1990), OJ No. 473 (HC)
33. *Van Dyke v Grey Bruce Regional Health Centre* (2005), Can LII 18841 (OnCA), para 58, (2005), OJ No. 2219, leave to appeal refused, (2005) SCCA No. 335
34. *Zaiffdeen v Chua* (2005), ABCA 290 CanLII, (2005) AJ No. 1175 (CA)
35. *Bauer (Litigation Guardian of) v Seager* (2000), CarswellMan 491, (2000) MJ No. 356 (QB)
36. Crouch R, Elliott R, Lemmens T, Charland L. Duty of care in obtaining informed consent; and Standard of care for treatment with complementary/alternative therapies. In: *Complementary/Alternative Health Care and HIV/AIDS*. Toronto, Ontario, Canada: Canadian HIV/AIDS Legal Network; 2001:93–94
37. Hawkins P, Ghosn J. Alternative therapies. In: Borden Ladner Gervais LLP, ed. *Canadian Health Law Practice Manual*. Looseleaf ed (including 2009 service issues). Markham, Ontario, Canada: LexisNexis; 2000
38. *Santos v Traff* (1999), ABQB 630, (1999) AJ No. 931 (QB), para 49
39. Knoll A. The reawakening of complementary and alternative medicine at the turn of the twenty-first century: filling the void in conventional biomedicine. *J Contemp Health Law Policy*. 2004;20(2):329–366
40. College of Physicians and Surgeons of Ontario. Complementary medicine: policy 1-00. Available at: www.cpso.on.ca/policies/policies/default.aspx?ID=1532. Accessed August 20, 2010
41. Rudolph CD, Rudolph AM, ed. *Rudolph's Pediatrics*. 21st ed. New York, NY: McGraw-Hill; 2003
42. Ezzo J, Vickers J, Richardson MA, et al. Acupuncture-point stimulation for chemotherapy-induced nausea or vomiting. *Cochrane Database Syst Rev*. 2006;(2): CD002285
43. Dibble SL, Luce J, Cooper BA, et al. Acupressure for chemotherapy-induced nausea and vomiting: a randomized clinical trial. *Oncol Nurs Forum*. 2007;34(4):813–820
44. Roscoe JA, Bushunow P, Jean-Pierre P, et al. Acupressure bands are effective in reducing radiation therapy-related nausea. *J Pain Symptom Manage*. 2009;38(3):381–389
45. Jones E, Isom S, Kemper K, McLean T. Acupressure for chemotherapy-associated nausea and vomiting in children. *J Soc Integr Oncol*. 2008;6(4):141–145
46. Molassiotis A, Helin AM, Dabbour R, Hummerston S. The effects of P6 acupressure in the prophylaxis of chemotherapy-related nausea and vomiting in breast cancer patients. *Complement Ther Med*. 2007;15(1):3–12
47. Kaptchuk TJ. Acupuncture: theory, efficacy, and practice. *Ann Intern Med*. 2002;136(5):374–383
48. White A, Hayhoe S, Hart A, Ernst E, BMAS and AACP, British Medical Acupuncture Society and Acupuncture Association of Chartered Physiotherapists. Survey of Adverse Events Following Acupuncture (SAFA): a prospective study of 32,000 consultations. *Acupunct Med*. 2001;19(2):84–92
49. MacPherson H. Fatal and adverse events from acupuncture: allegation, evidence, and the implications. *J Altern Complement Med*. 1999;5(1):47–56
50. Ernst E, White A. Life-threatening adverse reactions after acupuncture? A systematic review. *Pain*. 1997;71(2):123–126
51. Weiger WA, Smith M, Boon H, Richardson MA, Kaptchuk TJ, Eisenberg DM. Advising patients who seek complementary and alternative medical therapies for cancer. *Ann Intern Med*. 2002;137(11):889–903
52. Kemper KJ, Sarah R, Silver-Highfield E, Xiarhos E, Barnes L, Berde C. On pins and needles? Pediatric pain patients' experience with acupuncture. *Pediatrics*. 2000;105(4 pt 2):941–947
53. Highfield ES, McLellan MC, Kemper KJ, Risko W, Woolf AD. Integration of complementary and alternative medicine in a major pediatric teaching hospital: an initial overview. *J Altern Complement Med*. 2005;11(2):373–380
54. Zeltzer LK, Tsao JC, Stelling C, Powers M, Levy S, Waterhouse M. A phase I study on the feasibility and acceptability of an acupuncture/hypnosis intervention for chronic pediatric pain. *J Pain Symptom Manage*. 2002;24(4):437–446
55. Dundee JW, Ghaly RG, Fitzpatrick K, Lynch GA, Abram WP. Acupuncture to prevent cisplatin-associated vomiting. *Lancet*. 1987;1:1083
56. Reindl TK, Geilen W, Hartmann R, et al. Acupuncture against chemotherapy-induced nausea and vomiting in pediatric oncology: interim results of a multicenter crossover study. *Support Care Cancer*. 2006;14(2):172–176
57. Jindal V, Ge A, Mansky PJ. Safety and efficacy of acupuncture in children: a review of the evidence. *J Pediatr Hematol Oncol*. 2008;30(6):431–442
58. Gottschling S, Reindl TK, Meyer S, et al. Acupuncture to alleviate chemotherapy-induced nausea and vomiting in pediatric oncology: a randomized multicenter crossover pilot trial. *Klin Padiatr*. 2008;220(6):365–370
59. Cohen M. Legal and risk management issues in complementary and alternative medicine. In: Snyder L *Complementary and Alternative Medicine: Ethics, the Patient, and the Physician*. Totowa, NJ: Humana Press; 2007:167–200
60. Gilmour J, Harrison C, Cohen MH, Vohra S. Pediatric use of complementary and alternative medicine: legal, ethical, and clinical issues in decision-making. *Pediatrics*. 2011;128(5 pt 4):S149–S154

Informed Consent: Advising Patients and Parents About Complementary and Alternative Medicine Therapies

Joan Gilmour, Christine Harrison, Leyla Asadi, Michael H. Cohen and Sunita Vohra

Pediatrics 2011;128;S187

DOI: 10.1542/peds.2010-2720H

| | |
|---|--|
| Updated Information & Services | including high resolution figures, can be found at: http://pediatrics.aappublications.org/content/128/Supplement_4/S187 |
| References | This article cites 29 articles, 5 of which you can access for free at: http://pediatrics.aappublications.org/content/128/Supplement_4/S187#BIBL |
| Subspecialty Collections | This article, along with others on similar topics, appears in the following collection(s): Pharmacology http://www.aappublications.org/cgi/collection/pharmacology_sub Therapeutics http://www.aappublications.org/cgi/collection/therapeutics_sub |
| Permissions & Licensing | Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at: http://www.aappublications.org/site/misc/Permissions.xhtml |
| Reprints | Information about ordering reprints can be found online: http://www.aappublications.org/site/misc/reprints.xhtml |

American Academy of Pediatrics

DEDICATED TO THE HEALTH OF ALL CHILDREN™



PEDIATRICS®

OFFICIAL JOURNAL OF THE AMERICAN ACADEMY OF PEDIATRICS

Informed Consent: Advising Patients and Parents About Complementary and Alternative Medicine Therapies

Joan Gilmour, Christine Harrison, Leyla Asadi, Michael H. Cohen and Sunita Vohra

Pediatrics 2011;128;S187

DOI: 10.1542/peds.2010-2720H

The online version of this article, along with updated information and services, is located on the World Wide Web at:

http://pediatrics.aappublications.org/content/128/Supplement_4/S187

Pediatrics is the official journal of the American Academy of Pediatrics. A monthly publication, it has been published continuously since 1948. Pediatrics is owned, published, and trademarked by the American Academy of Pediatrics, 141 Northwest Point Boulevard, Elk Grove Village, Illinois, 60007. Copyright © 2011 by the American Academy of Pediatrics. All rights reserved. Print ISSN: 1073-0397.

American Academy of Pediatrics

DEDICATED TO THE HEALTH OF ALL CHILDREN™

